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D-phenylglycineas chiral stationaryphase.Enantiomericpurity 01stereoisomersis determinedby HPLC-CSP
techniqueand configurationsdeducedvia X-ray crystallography.
The4-aryl-l ,4-dihydropyridines1first prepare<!byHantzsch2haveattractedsubstantialattentionsincethediscovery
of theircalcium antagonistsproperties.3Their subsequentherapeuticalapplicationshas led to an enormouseffort being
devotedto theclinical developmentof new derivatives.The symmetricallysubstituteddimethyl2.6-dimethyl-4-(o-nitro-
phenyl)-1,4-dihydropyridine-3.S-dicarboxylate(Nifedipine) wasthefirst l,4-dihydropyridineusedclinically againstangina
pectorisandhypertension.4More recentpharmacologicalstudieson othermembersof this classof drugshasshownthat
the enantiomersof chiral 1,4-dihydropyridines such as nimodipine and nicardipine exhibited not oniy activities
quantitativelydifferent but also qualitatively.5Moreover, thereare evenexamplesin which both enantiomershave the
oppositeactionprofile with one of the enantiomersbeing a calcium antagonistand theotherone a calcium agonist In
viewof thegreatimportanceof chirality 10pharmacologicalactivity in thesedrugs.the separationof enantiomersor the
developmentof stereoselectivesynthesesis of great interest for obtaining new and more selective molecules with
therapeuticalapplications.6
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1 (Fumidipine)R' = R2=Me ;R3=2"NC:l:!(Nifedipine)
R' = i-Pr; R2=CH¡:HpMe ;R3=3-NO"(Nimodipine)







As resultof a screeningby Cermol S.A. laboratoriesof thecalcium antagonistactivityof numerous4-aryldihydro-
pyridine-3.5-dicarboxilateswe have found that methyl tetrahydrofuran-2-ylmethyl2.6-dimethyl-4-(o-nitrophenyl)-1,4-
dihydropyridine-3.5-dicarboxylate1 (furnidipine), is a new, highly active and specific calcium antagonist.This
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dihydropyridinederivativeis also a chira! structureand existsas four stereoisomers,alI of themneededin
enantiomericalIypureformforpharmacologicalstudiesdirecledlo determinepossibleactivitydifferences.
OplicalIyactive1,4-dihydropyridineshavebeenpreparedeitherby chemicalor enzymaticresolutionof the
racematesor bychira!chromatographicseparationof theantipodes.7The preparationof purefourstereoisomersof 1
wasfirstattemptedbyadaptingthemethodreportedbyShibanumandco-workers8withtheacid
4 by resolutionof 5-methoxycarbonyl-2,6-dimethyl-4-(o-nitrophenyl)-1,4-dihydropyridine-3-
carboxylicacid3andesterificationoftheacidwithenantiomericpuretetrahydrofurfurylalcohol.












(R)-tetrahydrofurfurylalcohols.12•13Funherelaborationi todiaslereomericfurnidipinela andlb viaamodifiedHantzsch
synthesis14,15is shownin Scheme3. In bothpossibleroutesla and lb wereobtainedas a (50:50)mixtureof
diastereomersandno diastereomericexcesswasdetectedunderdifferentconditions.
Theseparationof diaslereomerswascarriedOulbychira!preparativeHPLC usingaPirklecolumn(250x 30mm
Ld.)packedwithD-phenylglycine.16Samples(0.5mI)wereinjectedassolutionsin theeluent(dichIoromethane)ataflow
rateof 22 m1/minanddetecledby absorbanceat 254nm. In a typicalseparationa dichIoromethanesolutionof
furnidipinela (c=80mg/mI)affordedfourfractions(F1-F4 in Figure1)whichafterbeingrechromatographed(twicefor
F3) gavepurediaslereomers(>99%d.e.).
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Agure 1.Analy1icalchromatDgramfrem!hechiralHPlC 01a mixture01R,5-1 and S,5-1 on a Pirkle
column(250x 4.6 mmi.d.).Samples(20¡!l,e 0.1mg/ml)were injectedindichlorometaneas a flowrate01
1.5mllminand detectedby absorbanceat 335 nm.
Theenantiomericpurityof thefourstereoisomersof 1 (Scheme3)wasalsodeterminedbyHPLC-CSPbyusing
an(ll-acidglycoproteincolumn17(100x 4.6mmLd.)withH20/i-PrOH(9:1)aseluentanda flow rateof 0.2m1/min.
A 20¡ll injecledsample(e=0.1mg/ml)detecledbyabsorbanceal 335nmgaveretentiontimesbelween24and32min
for thestereoisomers.
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I 99%e.e. 1 (3)
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(2) 1>99%d.9.j
(3) 1 94% 9.9.
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1>99%d.9.j (2)
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Scheme3. Simplifiedsynthesisof fumidipine.i)Jones'sreagent,acetone,O °C; ii) For resolutionof theacidand




(1) Determinedby lH_NMR analysiswithEu(hfc)3;(2) DeterminedbyHPLC-CSP (Pirldeco1umn,seetext);
(3) Determinedby HPLC-CSP (a¡-acidglycoproteincolumn,seetext).
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The assignedconfigurationsweredetermined
by subjectinga crystalof racemicfumidipine1
purified by fractional crystallizationlO X-Ray
diffraction analysis (Figure 2). The racemate
(R,RIS,S)-1 crystallizesin the triclinic systemP-I
with unit cell dimensionsa=8.127(1),b=1O.603(1),





collected(1551reflections)with a Nonius CAD-4
automaticfour-circlediffractometer.18
Figure 2. Stereoscopicviewof (R,RlS,S)-1
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